Gordon Li, MD

Professor and Vice Chair, Faculty Affairs
Stanford University Department of Neurosurgery
Stanford, California, United States

Gordon Li is a Professor and Vice Chair of Faculty Affairs in the Department of Neurosurgery at Stanford University School of Medicine. He is a brain tumor surgeon who runs a basic science lab, brain tumor clinical trials, and takes care of brain tumor patients in the operating room, clinic and with CyberKnife radiosurgery. He is also the associate dean of academic affairs for Stanford University School of Medicine

Presentation(s):

• (NC5505) Endoscopic Approaches Are Associated with Superior Visual Outcomes: The Simpson Grade Is Irrelevant

  Monday, April 24, 2023
  8:25am – 8:41am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) The Data Supporting the Open Treatment of Suprasellar Meningiomas: The Simpson Grade Is Alive and Well

  Monday, April 24, 2023
  8:42am – 8:58am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) Radiosurgery Is Ticky, but Works…indications, Limitations and Long-term Outcomes

  Monday, April 24, 2023
  8:59am – 9:15am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) Molecular Strategy to Meningioma

  Monday, April 24, 2023
  9:16am – 9:32am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) Atypical Meningiomas. Surgery and Radiation

  Monday, April 24, 2023
  9:33am – 9:49am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) MIS Approaches to Meningioma

  Monday, April 24, 2023
  9:50am – 10:06am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) AI Advancements in Meningioma

  Monday, April 24, 2023
  10:07am – 10:23am PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)

• (NC5505) Molecular Targeting of Glioblastoma

  Monday, April 24, 2023
  12:23pm – 12:37pm PST

  Disclosure(s): Abbott: Stock Shareholder (excluding mutual funds) (Ongoing); Biogen: Stock Shareholder (excluding mutual funds) (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Bristol Myers Squibb: Grant/Research Support (Terminated, February 6, 2023); gilead: Stock Shareholder (excluding mutual funds) (Ongoing); J&J/Synthes: Speaker/Honoraria (Terminated, February 6, 2023); Medtronic: Consultant (Ongoing); Merck: Stock Shareholder (excluding mutual funds) (Ongoing); Novocure: Grant/Research Support (Ongoing); Pfizer: Stock Shareholder (excluding mutual funds) (Ongoing); Photonic Medical: Advisor (Ongoing), Consultant (Ongoing), Ownership Interest (Ongoing); stryker: Stock Shareholder (excluding mutual funds) (Ongoing)